1-43338136-G-T

Variant summary

Our verdict is Benign. The variant received -19 ACMG points: 1P and 20B. PP2BP4_StrongBP6_Very_StrongBS1BS2

The NM_005373.3(MPL):​c.117G>T​(p.Lys39Asn) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00254 in 1,614,194 control chromosomes in the GnomAD database, including 75 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.013 ( 39 hom., cov: 33)
Exomes 𝑓: 0.0014 ( 36 hom. )

Consequence

MPL
NM_005373.3 missense

Scores

1
17

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:11O:2

Conservation

PhyloP100: -0.0550

Publications

42 publications found
Variant links:
Genes affected
MPL (HGNC:7217): (MPL proto-oncogene, thrombopoietin receptor) In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs . TPO-R deficient mice were severely thrombocytopenic, emphasizing the important role of CD110 and thrombopoietin in megakaryocyte and platelet formation. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated. [provided by RefSeq, Jul 2008]
MPL Gene-Disease associations (from GenCC):
  • thrombocythemia 2
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Ambry Genetics, ClinGen
  • congenital amegakaryocytic thrombocytopenia
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Orphanet, Ambry Genetics
  • congenital amegakaryocytic thrombocytopenia 1
    Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
  • familial thrombocytosis
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • hereditary isolated aplastic anemia
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -19 ACMG points.

PP2
Missense variant in the gene, where a lot of missense mutations are associated with disease in ClinVar. The gene has 25 curated pathogenic missense variants (we use a threshold of 10). The gene has 7 curated benign missense variants. Gene score misZ: 0.39478 (below the threshold of 3.09). Trascript score misZ: 1.6963 (below the threshold of 3.09). GenCC associations: The gene is linked to hereditary isolated aplastic anemia, congenital amegakaryocytic thrombocytopenia, thrombocythemia 2, congenital amegakaryocytic thrombocytopenia 1, familial thrombocytosis.
BP4
Computational evidence support a benign effect (MetaRNN=0.0097358525).
BP6
Variant 1-43338136-G-T is Benign according to our data. Variant chr1-43338136-G-T is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 14162.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS1
Variant frequency is greater than expected in population afr. GnomAd4 allele frequency = 0.0131 (1999/152302) while in subpopulation AFR AF = 0.0452 (1877/41554). AF 95% confidence interval is 0.0435. There are 39 homozygotes in GnomAd4. There are 950 alleles in the male GnomAd4 subpopulation. Median coverage is 33. This position passed quality control check.
BS2
High Homozygotes in GnomAd4 at 39 AD,AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
MPLNM_005373.3 linkc.117G>T p.Lys39Asn missense_variant Exon 2 of 12 ENST00000372470.9 NP_005364.1 P40238-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
MPLENST00000372470.9 linkc.117G>T p.Lys39Asn missense_variant Exon 2 of 12 1 NM_005373.3 ENSP00000361548.3 P40238-1
MPLENST00000413998.7 linkc.96G>T p.Lys32Asn missense_variant Exon 2 of 12 1 ENSP00000414004.3 Q5JUY5
MPLENST00000638732.1 linkn.117G>T non_coding_transcript_exon_variant Exon 2 of 10 1

Frequencies

GnomAD3 genomes
AF:
0.0131
AC:
2000
AN:
152184
Hom.:
39
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.0453
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00523
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000414
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00316
Gnomad NFE
AF:
0.000353
Gnomad OTH
AF:
0.00716
GnomAD2 exomes
AF:
0.00354
AC:
889
AN:
251454
AF XY:
0.00257
show subpopulations
Gnomad AFR exome
AF:
0.0457
Gnomad AMR exome
AF:
0.00237
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000360
Gnomad OTH exome
AF:
0.00277
GnomAD4 exome
AF:
0.00144
AC:
2100
AN:
1461892
Hom.:
36
Cov.:
33
AF XY:
0.00124
AC XY:
903
AN XY:
727246
show subpopulations
African (AFR)
AF:
0.0450
AC:
1506
AN:
33480
American (AMR)
AF:
0.00279
AC:
125
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26136
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39700
South Asian (SAS)
AF:
0.000139
AC:
12
AN:
86258
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
53420
Middle Eastern (MID)
AF:
0.00399
AC:
23
AN:
5768
European-Non Finnish (NFE)
AF:
0.000205
AC:
228
AN:
1112010
Other (OTH)
AF:
0.00341
AC:
206
AN:
60396
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.483
Heterozygous variant carriers
0
131
263
394
526
657
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
52
104
156
208
260
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0131
AC:
1999
AN:
152302
Hom.:
39
Cov.:
33
AF XY:
0.0128
AC XY:
950
AN XY:
74452
show subpopulations
African (AFR)
AF:
0.0452
AC:
1877
AN:
41554
American (AMR)
AF:
0.00522
AC:
80
AN:
15312
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5168
South Asian (SAS)
AF:
0.000414
AC:
2
AN:
4830
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10620
Middle Eastern (MID)
AF:
0.00340
AC:
1
AN:
294
European-Non Finnish (NFE)
AF:
0.000353
AC:
24
AN:
68026
Other (OTH)
AF:
0.00709
AC:
15
AN:
2116
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.499
Heterozygous variant carriers
0
97
195
292
390
487
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
22
44
66
88
110
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00536
Hom.:
38
Bravo
AF:
0.0149
TwinsUK
AF:
0.000270
AC:
1
ALSPAC
AF:
0.00
AC:
0
ESP6500AA
AF:
0.0488
AC:
215
ESP6500EA
AF:
0.000698
AC:
6
ExAC
AF:
0.00441
AC:
535
Asia WGS
AF:
0.00231
AC:
8
AN:
3478
EpiCase
AF:
0.000709
EpiControl
AF:
0.000533

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:11Other:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:5
Mar 03, 2015
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is associated with the following publications: (PMID: 26568271, 15269348, 25525159, 24728327, 23511495, 24123366, 23103231) -

-
Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC)
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Genome Diagnostics Laboratory, University Medical Center Utrecht
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Mar 25, 2024
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Congenital amegakaryocytic thrombocytopenia Benign:2
Jan 07, 2020
Natera, Inc.
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Jun 14, 2016
Illumina Laboratory Services, Illumina
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Benign:1Other:1
Dec 10, 2021
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Sep 19, 2013
ITMI
Significance:not provided
Review Status:no classification provided
Collection Method:reference population

- -

Congenital amegakaryocytic thrombocytopenia 1 Benign:1
Feb 28, 2018
Counsyl
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com. -

Thrombocythemia 1 Benign:1
Jun 14, 2016
Illumina Laboratory Services, Illumina
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Essential thrombocythemia;C1327915:Congenital amegakaryocytic thrombocytopenia Benign:1
Jan 24, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Thrombocythemia 2 Other:1
Aug 03, 2004
OMIM
Significance:risk factor
Review Status:no assertion criteria provided
Collection Method:literature only

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.13
BayesDel_addAF
Benign
-0.54
T
BayesDel_noAF
Benign
-0.51
CADD
Benign
14
DANN
Uncertain
0.98
DEOGEN2
Benign
0.33
T;.
Eigen
Benign
-0.72
Eigen_PC
Benign
-0.53
FATHMM_MKL
Benign
0.35
N
LIST_S2
Benign
0.50
T;T
MetaRNN
Benign
0.0097
T;T
MetaSVM
Benign
-1.0
T
MutationAssessor
Benign
-1.4
N;.
PhyloP100
-0.055
PrimateAI
Benign
0.29
T
PROVEAN
Benign
-1.3
N;.
REVEL
Benign
0.23
Sift
Benign
0.49
T;.
Sift4G
Benign
0.16
T;.
Polyphen
0.0060
B;.
Vest4
0.064
MutPred
0.12
Loss of methylation at K39 (P = 3e-04);.;
MVP
0.62
MPC
0.22
ClinPred
0.0075
T
GERP RS
1.6
PromoterAI
0.00080
Neutral
Varity_R
0.078
gMVP
0.59
Mutation Taster
=96/4
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.13
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs17292650; hg19: chr1-43803807; COSMIC: COSV65244776; API